California Prop 65 and Tampax — What the MADL Means for Your Claim in 2026

Today is July 8, 2026, and our joint team of legal and toxicological experts is dissecting the precise legal thresholds regarding California Prop 65 and Tampax — what the MADL means for your claim in ongoing federal litigation.

As practitioners actively monitoring multidistrict litigation and mass tort dockets, we evaluate these consumer claims through a strictly evidence-based lens.

Toxicological Thresholds in California Prop 65 and Tampax — what the MADL means for your claim

The legal foundation of the current Tampax litigation rests on independent laboratory testing that detected trace heavy metals in widely distributed menstrual products.

• Lead (Pb)
• Arsenic (As)
• Cadmium (Cd)

The scientific community's focus shifted sharply in August 2024 following a landmark publication in the journal Environment International (DOI: 10.1016/j.envint.2024.108849).

"We found 12 of the 16 metals we tested for, including some toxic metals like lead, present in 100% of the tampons we tested," stated Dr. Jenni Shearston, lead author and environmental epidemiologist at UC Berkeley.

Our toxicological review of the Shearston data confirms that researchers utilized microwave-acid digestion and Inductively Coupled Plasma Mass Spectrometry (ICP-MS) to quantify these metals.

Analyzing the Proposition 65 Framework

The Safe Drinking Water and Toxic Enforcement Act of 1986, commonly known as Proposition 65, establishes specific daily exposure limits for known toxins.

1. Requires businesses to provide clear warnings before exposing consumers to listed chemicals.
2. Designates a Maximum Allowable Dose Level (MADL) for chemicals causing reproductive toxicity.
3. Sets the exact MADL for lead at 0.5 micrograms (µg) per day.

The central allegation in federal complaints, such as Barton v. The Procter & Gamble Company (No. 3:24-cv-01332, S.D. Cal.), relies heavily on this specific toxicological threshold.

According to independent lab tests cited in the Barton docket, lead levels in individual Tampax Pearl tampons demonstrated significant variations across product lines.

• Tampax Pearl Light: 0.243 µg per tampon
• Tampax Pearl Regular: 0.181 µg per gram of material
• Tampax Pearl Ultra: 0.787 µg per tampon

When analyzing these figures, our toxicologists look directly at the dose-response relationship and the cumulative daily exposure.

Cumulative Exposure and Vaginal Absorption

Manufacturers generally advise consumers to change tampons every four to eight hours, resulting in the use of three to six tampons per 24-hour period.

According to the plaintiffs' mathematical models, women using three to six Pearl Ultra tampons daily would be exposed to between 0.729 µg and 4.722 µg of lead, significantly exceeding the 0.5 µg MADL.

From a clinical toxicology standpoint, vaginal mucosa presents a uniquely vulnerable route of administration.

• The vaginal epithelium is highly vascularized.
• Absorption bypasses the liver's first-pass metabolic filtration.
• Contaminants enter systemic circulation directly.

Because lead is a cumulative toxicant that bioaccumulates in bone and blood over time, even trace microgram exposures warrant rigorous medical scrutiny.

Procedural Posture: California Prop 65 and Tampax — what the MADL means for your claim

As seasoned litigators, we must distinguish between alarming scientific headlines and actionable legal claims that can survive a Rule 12(b)(6) motion to dismiss.

The Survival of the Barton Litigation

In August 2025, U.S. District Judge Gonzalo P. Curiel issued a pivotal order (Document 50) shaping the trajectory of the Procter & Gamble litigation.

• Granted dismissal of specific unfair competition claims based on standing.
• Denied dismissal of core consumer protection and economic loss claims.
• Allowed the California Consumers Legal Remedies Act (CLRA) claims to proceed to discovery.

This ruling signals that federal courts find the MADL threshold argument legally sufficient to warrant evidentiary discovery.

"Plaintiffs have plausibly alleged that the ordinary and intended use of the Products exposed consumers to unsafe levels of lead exceeding California's Proposition 65 MADL," the court noted during early pleadings.

Following this survival, plaintiffs' attorneys across the country initiated similar class actions in other jurisdictions.

Expansion of the Docket in 2025 and 2026

By late 2025 and early 2026, the litigation expanded beyond California's borders, testing the viability of the MADL standard in federal courts nationwide.

1. November 2025: Sanchez et al. v. P&G (Case No. 1:25-cv-00852-DRC) filed in the Southern District of Ohio.
2. January 2026: Otkina et al. v. P&G filed in the Northern District of Illinois by eight plaintiffs.

These subsequent filings universally rely on the baseline established by the initial Prop 65 MADL calculations.

However, proving that a product contains a toxicant is not legally synonymous with proving that the toxicant caused a specific personal injury.

Professional Analysis: Evaluating Tampax Heavy Metal Litigation

Our multidisciplinary team evaluates these dockets daily, and the current procedural posture reveals a calculated strategy by the plaintiffs' bar.

The Economic Loss Strategy

To date, these lawsuits are fundamentally consumer fraud and economic loss class actions, rather than traditional personal injury mass torts.

• Plaintiffs are not currently required to prove specific blood-lead elevation.
• The injury alleged is the financial premium paid for a purportedly safe product.
• The legal theory hinges on failure to warn and deceptive marketing.

As plaintiffs' counsel, we recognize that bridging the causation gap for personal injury requires overcoming stringent Daubert standards.

To prove a personal injury claim, an expert toxicologist must demonstrate that the heavy metals actually leached from the rayon/cotton matrix, crossed the mucosal barrier in sufficient quantities, and directly caused the plaintiff's specific adverse health outcome.

This exact evidentiary hurdle is why the FDA's current scientific intervention is the most critical variable in the 2026 legal landscape.

The FDA's Regulatory Investigation

On September 10, 2024, the FDA formally acknowledged the Environment International findings and initiated an internal regulatory review.

• Commissioned an independent literature review of heavy metals in feminine hygiene products.
• Launched an internal bench laboratory study to simulate actual tampon use.
• Focused specifically on measuring the leaching rate of metals under physiological conditions.

If the FDA bench studies, expected to yield peer-reviewed results later this year, confirm that lead leaches at rates exceeding the MADL, the settlement value of these consumer claims will multiply exponentially.

Statutory Claims Under California Law

To understand why the MADL threshold is dispositive, our attorneys emphasize the three primary California statutes invoked by plaintiffs.

• Consumers Legal Remedies Act (CLRA): Prohibits deceptive practices in consumer transactions.
• Unfair Competition Law (UCL): Targets unlawful, unfair, or fraudulent business acts.
• False Advertising Law (FAL): Penalizes untrue or misleading product marketing.

By alleging that Procter & Gamble failed to provide Prop 65 warnings despite internal knowledge, plaintiffs trigger strict liability frameworks under these statutes.

"Consumers therefore must and do rely on Defendant to disclose and truthfully report what their Products contain on their packaging or labels," the Barton complaint asserts.

This reliance argument is the exact mechanism plaintiffs use to certify a nationwide class, bypassing the need to prove individualized physical harm.

Understanding Lead Biomarkers and Testing

From a toxicological vantage point, our experts continuously evaluate the biomarkers required to prove causation if these cases evolve into personal injury claims.

• Blood Lead Levels (BLL) indicate recent systemic exposure.
• Bone lead measurements using K-shell X-ray fluorescence (KXRF) reveal historical accumulation.
• Isotopic ratio analysis can theoretically trace the origin of the lead back to specific environmental sources.

Because lead mimics calcium in the human body, it crosses the blood-brain barrier and placental barrier with alarming efficiency.

Until these isotopic tracing methodologies are presented in a Daubert hearing, the economic loss strategy remains the plaintiffs' safest path forward.

Litigation Strategy: California Prop 65 and Tampax — what the MADL means for your claim

From a defense perspective, P&G continues to argue that trace metals exist ubiquitously in soil and water, naturally absorbing into cotton crops without corporate negligence.

The Ubiquity Defense

Corporate defendants consistently leverage the "background exposure" argument in toxic tort litigation.

1. Arguing that the detected lead levels are lower than EPA drinking water action levels.
2. Asserting that the manufacturing process does not intentionally add heavy metals.
3. Demanding plaintiffs prove the metals are biologically available (capable of leaching).

Our review of the Otkina complaint highlights a direct counter to this defense, noting that Tampax tampons allegedly contain up to 40 times more lead than the EPA's drinking water standard when adjusted for direct mucosal exposure.

"Lead exposure through vaginal absorption is especially dangerous because it bypasses the liver's metabolic functions, increasing the systemic bioavailability of the neurotoxin," the Illinois plaintiffs allege.

This physiological distinction neutralizes the defense's attempt to compare tampon exposure to oral ingestion of drinking water or food products.

What This Means For You: Next Steps in the Litigation

For consumers actively monitoring these dockets, protecting your legal rights requires deliberate documentation.

Actionable Steps for Consumers

Until federal judges certify these proposed classes or the MDL panel consolidates the dockets, evidence preservation remains your primary responsibility.

• Retain all physical receipts and digital purchase histories for Tampax products.
• Photograph the lot numbers and barcodes on any remaining product packaging in your possession.
• Do not mail your physical product to a laboratory without consulting a licensed attorney, as destructive testing can spoil evidence.

If you have experienced unexplained reproductive or systemic health issues and have a documented history of long-term Tampax use, consult a physician regarding a standard blood heavy metal panel.

Looking Ahead to Late 2026

The upcoming quarters will dictate whether these individual class actions consolidate into a formalized Multidistrict Litigation (MDL).

1. Awaiting the final publication of the FDA's bench laboratory leaching study.
2. Monitoring the class certification hearings in the Southern District of California.
3. Tracking potential settlement discussions if summary judgment motions fail.

Our attorneys will continue updating our databases as these critical judicial milestones approach.

Conclusion

The intersection of public health research and consumer protection law has placed Procter & Gamble under unprecedented federal scrutiny. As courts continue to interpret the precise applications of California Prop 65 and Tampax — what the MADL means for your claim remains the definitive legal benchmark for assessing corporate liability. We will update this analysis the moment the FDA releases its highly anticipated leaching data or Judge Curiel issues the next scheduling order in the California docket.